End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.
Identifieur interne : 000505 ( Ncbi/Checkpoint ); précédent : 000504; suivant : 000506End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.
Auteurs : Nicolas Simon [France] ; Joëlle Micallef ; Jean-Charles Reynier ; Monique Lesourd ; Tatiana Witjas ; André Alicherif ; Jean-Philippe Azulay ; Olivier BlinSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.
English descriptors
- KwdEn :
- Aged, Dopamine Agonists (blood), Dopamine Agonists (therapeutic use), Dose-Response Relationship, Drug, Drug Evaluation (methods), Female, Humans, Infusions, Intravenous (methods), Male, Middle Aged, Parkinson Disease (blood), Parkinson Disease (drug therapy), Piribedil (blood), Piribedil (therapeutic use), Retrospective Studies, Severity of Illness Index, Time Factors, Treatment Outcome.
- MESH :
- chemical , blood : Dopamine Agonists, Piribedil.
- chemical , therapeutic use : Dopamine Agonists, Piribedil.
- blood : Parkinson Disease.
- drug therapy : Parkinson Disease.
- methods : Drug Evaluation, Infusions, Intravenous.
- Aged, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment Outcome.
Abstract
This randomized, double-blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from off to on state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2-16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing off state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16-mg dose and pharmacokinetics were linear up to the 16-mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from off-->on. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients.
DOI: 10.1002/mds.20400
PubMed: 15726579
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000F40
- to stream PubMed, to step Curation: 000F00
- to stream PubMed, to step Checkpoint: 000F00
- to stream Ncbi, to step Merge: 000505
- to stream Ncbi, to step Curation: 000505
Links to Exploration step
pubmed:15726579Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.</title><author><name sortKey="Simon, Nicolas" sort="Simon, Nicolas" uniqKey="Simon N" first="Nicolas" last="Simon">Nicolas Simon</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name></author><author><name sortKey="Reynier, Jean Charles" sort="Reynier, Jean Charles" uniqKey="Reynier J" first="Jean-Charles" last="Reynier">Jean-Charles Reynier</name></author><author><name sortKey="Lesourd, Monique" sort="Lesourd, Monique" uniqKey="Lesourd M" first="Monique" last="Lesourd">Monique Lesourd</name></author><author><name sortKey="Witjas, Tatiana" sort="Witjas, Tatiana" uniqKey="Witjas T" first="Tatiana" last="Witjas">Tatiana Witjas</name></author><author><name sortKey="Alicherif, Andre" sort="Alicherif, Andre" uniqKey="Alicherif A" first="André" last="Alicherif">André Alicherif</name></author><author><name sortKey="Azulay, Jean Philippe" sort="Azulay, Jean Philippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name></author><author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15726579</idno><idno type="pmid">15726579</idno><idno type="doi">10.1002/mds.20400</idno><idno type="wicri:Area/PubMed/Corpus">000F40</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F40</idno><idno type="wicri:Area/PubMed/Curation">000F00</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F00</idno><idno type="wicri:Area/PubMed/Checkpoint">000F00</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F00</idno><idno type="wicri:Area/Ncbi/Merge">000505</idno><idno type="wicri:Area/Ncbi/Curation">000505</idno><idno type="wicri:Area/Ncbi/Checkpoint">000505</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.</title><author><name sortKey="Simon, Nicolas" sort="Simon, Nicolas" uniqKey="Simon N" first="Nicolas" last="Simon">Nicolas Simon</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire Timone, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name></author><author><name sortKey="Reynier, Jean Charles" sort="Reynier, Jean Charles" uniqKey="Reynier J" first="Jean-Charles" last="Reynier">Jean-Charles Reynier</name></author><author><name sortKey="Lesourd, Monique" sort="Lesourd, Monique" uniqKey="Lesourd M" first="Monique" last="Lesourd">Monique Lesourd</name></author><author><name sortKey="Witjas, Tatiana" sort="Witjas, Tatiana" uniqKey="Witjas T" first="Tatiana" last="Witjas">Tatiana Witjas</name></author><author><name sortKey="Alicherif, Andre" sort="Alicherif, Andre" uniqKey="Alicherif A" first="André" last="Alicherif">André Alicherif</name></author><author><name sortKey="Azulay, Jean Philippe" sort="Azulay, Jean Philippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name></author><author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Dopamine Agonists (blood)</term><term>Dopamine Agonists (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Drug Evaluation (methods)</term><term>Female</term><term>Humans</term><term>Infusions, Intravenous (methods)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (blood)</term><term>Parkinson Disease (drug therapy)</term><term>Piribedil (blood)</term><term>Piribedil (therapeutic use)</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Dopamine Agonists</term><term>Piribedil</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term><term>Piribedil</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Evaluation</term><term>Infusions, Intravenous</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This randomized, double-blind trial was designed to define the possible relationship between piribedil plasma concentrations and the decrease of the Unified Parkinson's Disease Rating Scale (UPDRS) motor score or the switch from off to on state after single intravenous infusion. Ten fluctuating patients with idiopathic Parkinson's disease (PD) received escalating doses of piribedil (2-16 mg) and placebo. Starting from 2 mg, piribedil was effective in reducing the motor deficit (UPDRS, motor score) including akinesia at the first evaluation time point of 15 minutes, and in reversing off state of 7 of 10 patients. The doses were equally effective, although the effect was more sustained with the highest dose of 16 mg. Piribedil was well tolerated up to a 16-mg dose and pharmacokinetics were linear up to the 16-mg dose. Plasma levels of piribedil were not correlated to the motor score improvement or switch from off-->on. In conclusion, a short single infusion of piribedil at 2 to 16 mg was safe and effective in improving motor symptoms, including akinesia, of fluctuating PD patients.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Provence-Alpes-Côte d'Azur</li></region><settlement><li>Marseille</li></settlement></list><tree><noCountry><name sortKey="Alicherif, Andre" sort="Alicherif, Andre" uniqKey="Alicherif A" first="André" last="Alicherif">André Alicherif</name><name sortKey="Azulay, Jean Philippe" sort="Azulay, Jean Philippe" uniqKey="Azulay J" first="Jean-Philippe" last="Azulay">Jean-Philippe Azulay</name><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name><name sortKey="Lesourd, Monique" sort="Lesourd, Monique" uniqKey="Lesourd M" first="Monique" last="Lesourd">Monique Lesourd</name><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name><name sortKey="Reynier, Jean Charles" sort="Reynier, Jean Charles" uniqKey="Reynier J" first="Jean-Charles" last="Reynier">Jean-Charles Reynier</name><name sortKey="Witjas, Tatiana" sort="Witjas, Tatiana" uniqKey="Witjas T" first="Tatiana" last="Witjas">Tatiana Witjas</name></noCountry><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Simon, Nicolas" sort="Simon, Nicolas" uniqKey="Simon N" first="Nicolas" last="Simon">Nicolas Simon</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000505 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000505 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:15726579
|texte= End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:15726579" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |